Aspirin and risk of endometrial cancer: a case-control study from Italy.

Data on the role of aspirin on endometrial cancer risk are scanty. Here we provide additional information on the issue, using data from a multicentric Italian case-control study. The study was conducted between 1992 and 2006 in three Italian areas, on 442 cases with histologically confirmed endometrial cancer and 676 control women admitted to the same hospitals as cases for a wide spectrum of acute, non-neoplastic, non-gynaecological, non-hormone-related conditions, providing information on aspirin use. Odds ratios (OR) of endometrial cancer and corresponding 95% confidence intervals were calculated using multiple logistic regression models, including terms for sociodemographic characteristics, body mass index and hormonal and reproductive factors. Regular aspirin use was reported by 28 (6.3%) cases and 46 (6.8%) controls, corresponding to a multivariate OR of 0.65 (95% confidence interval 0.37-1.11). There was no consistent pattern of risk with duration of use, nor with age at first use, time since first use or time since last use. Further, there was no difference in risk estimates across strata of body mass index. This study--the first one from a population outside North America--adds relevant information on the absence of a consistent association between aspirin use and endometrial cancer risk, even in high-risk overweight and obese women.